

EndoDiagnosis Announces CReATe Fertility as First Canadian Clinic to Offer Tier 1 ENDOSURE Diagnostic Test for Endometriosis

November 25, 2025

Edmonton, AB - November 25, 2025 - PRESSADVANTAGE -

London, Ontario: Dr. John McNaught, FRCSC, OB/GYN, MD and his teams at CReATe Fertility and London Women's Health Care are focused on improving diagnosis of endometriosis at their London, Ontario fertility and women's health clinic. They are the first medical center in both Canada, and North America, to permanently adopt the Tier 1 ENDOSURE test, a non-invasive and rapid diagnostic test that supports clinicians in providing faster, more informed endometriosis diagnosis.

Endometriosis is a chronic inflammatory condition affecting millions of women globally and can cause significant pain, gastrointestinal symptoms, and infertility. Historically, diagnosis has taken an average 8.6 years globally, relying on imaging studies and invasive laparoscopic surgery accessed years after symptom onset. ENDOSURE offers a non-surgical option that takes 30-minutes, providing clinicians with a diagnostic result empowering them to diagnosis endometriosis in a single clinic visit.

CReATe Fertility London's Dr. John McNaught, FRCSC, OB/GYN, MD has shown leadership that reflects both professional knowledge and personal commitment to reducing delays and improving outcomes for his patients through earlier diagnosis of endometriosis, one of the major underlying causes of infertility. With ENDOSURE test adoption, Dr. McNaught is eliminating the risks and discomfort associated with surgery just to get a diagnosis, reducing barriers for patients seeking answers about their fertility or menstrual health. With earlier diagnosis facilitating personalized symptom management, fertility preservation strategies, and disease course monitoring, Dr. McNaught aims to improve outcomes and wellbeing for his patients through Tier 1 testing for endometriosis.

By providing patient access to ENDOSURE testing in both community and ART clinics, EndoDiagnosis the Canadian Distributors for ENDOSURE, aim to empower healthcare providers to diagnosis endometriosis at

first patient visit with objective data derived from measuring gastrointestinal myoelectrical activity (GIMA).

Guided by CEO Maria Porcellato and COO Carolyn Plican, EndoDiagnosis combines healthcare expertise, education, and advocacy, to address diagnostic challenges inherent in endometriosis care. ?At EndoDiagnosis, we support a more timely and objective diagnostic process that can reduce uncertainty for women and clinicians alike,? says Porcellato. Plican adds, ?Partnering with clinics like CReATe Fertility in Ontario is an important step toward making rapid diagnosis accessible and the new standard in fertility care.?

ENDOSURE utilizes electroviscerography (EVG) technology to detect distinctive gastrointestinal myoelectrical activity (GIMA) seizure patterns unique to endometriosis sufferers, known as the ?GIMA biomarker?. During testing, sensors placed on the abdomen record this activity before and after a controlled water intake, capturing data for 30-minutes after water-load, which incites GIMA seizure patterns.

Clinical trials, with surgical confirmation, have shown high concordance between ENDOSURE results and laparoscopic findings, with published sensitivity and specificity metrics approaching or exceeding 95% in some cohorts. A landmark study published in the Journal of Clinical Medicine substantiated ENDOSURE?s ability to detect endometriosis even in patients with negative ultrasound or MRI imaging results, highlighting its potential to complement existing diagnostic modalities. 1 ENDOSURE is intended to serve as a clinical decision support tool, with results interpreted alongside clinical assessment to guide diagnosis and treatment planning.

Traditional diagnosis often involves imaging methods such as transvaginal ultrasound or MRI, which can reliably detect deep infiltrating endometriosis but may miss superficial lesions. The current gold standard, laparoscopic surgery, provides direct visualization and histopathologic confirmation but is invasive, costly, and involves surgical risks.

ENDOSURE offers a non-invasive, painless diagnostic solution that requires no anesthesia or tissue biopsy. The complete test can be performed in under an hour, delivering objective physiological data to support accurate clinical decision-making. With costs significantly lower than surgical diagnostic procedures, ENDOSURE provides a more accessible first-line assessment for patients. By offering early, objective evidence of disease presence, it enables physicians to prioritize patients for further evaluation or treatment, potentially reducing unnecessary surgeries and diagnostic delays.

ENDOSURE has been authorized by Health Canada since 2021 as a Tier 1 diagnostic test for endometriosis.² As a non-invasive and non-active medical device, it has a high safety profile and can be performed on female patients of all ages in Canadian healthcare settings. While the test maintains research-only status in the U.S., EndoDiagnosis is actively advancing clinical availability and awareness in Canada through certified training and collaborative healthcare partnerships.

###

For more information about EndoDiagnosis Inc., contact the company here: EndoDiagnosis Inc. Carolyn Plican 1-833-439-3636 info@endodiagnosis.com 6903 142 Ave NW, Edmonton, AB T5C 2P1

EndoDiagnosis Inc.

EndoDiagnosis addresses the need for faster, more accurate endometriosis diagnosis in Canada. Led by Maria Porcellato, Carolyn Plican, and Dr. Mary Ellen Haggerty, it exclusively distributes ENDOSURE a Health Canada authorized test with 1 hour results.

Website: <https://endodiagnosis.com/>

Email: info@endodiagnosis.com

Phone: 1-833-439-3636



Powered by PressAdvantage.com